Research programme: immunoregulatory vaccines - igeneon

Drug Profile

Research programme: immunoregulatory vaccines - igeneon

Alternative Names: IGN-501; Immunoregulatory vaccines research programme - igeneon

Latest Information Update: 05 Nov 2009

Price : $50

At a glance

  • Originator igeneon Krebs-Immuntherapie Forschungs- und Entwicklungs-AG
  • Class Vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Autoimmune disorders; Cancer; Hypersensitivity

Most Recent Events

  • 05 Nov 2009 Discontinued - Preclinical for Cancer in Austria (unspecified route)
  • 05 Nov 2009 Discontinued - Preclinical for Autoimmune disorders in Austria (unspecified route)
  • 05 Nov 2009 Discontinued - Preclinical for Allergy in Austria (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top